TCGA-E5-A4U1-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 38.79763469
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.280
- KRAS_SIGNALING_DN+0.250
- SPERMATOGENESIS+0.220
- PANCREAS_BETA_CELLS+0.180
- BILE_ACID_METABOLISM+0.100
- OXIDATIVE_PHOSPHORYLATION+0.060
- PEROXISOME+0.030
- DNA_REPAIR+0.010
- FATTY_ACID_METABOLISM-0.100
- XENOBIOTIC_METABOLISM-0.110
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- INFLAMMATORY_RESPONSE-0.550
- IL6_JAK_STAT3_SIGNALING-0.540
- INTERFERON_GAMMA_RESPONSE-0.530
- INTERFERON_ALPHA_RESPONSE-0.510
- TGF_BETA_SIGNALING-0.490
- UV_RESPONSE_DN-0.490
- COMPLEMENT-0.470
- PROTEIN_SECRETION-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 264656b8-d45c-4f5c-a431-366c566296fe | — | — | 0.943 |
| 2 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.935 |
| 3 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.934 |
| 4 | SRR1474754 | GTEX | — | 0.930 |
| 5 | SRR1404969 | GTEX | — | 0.928 |
| 6 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.928 |
| 7 | SRR1456514 | GTEX | — | 0.928 |
| 8 | aMVAC.P_005_TURBT_S223 | — | — | 0.925 |
| 9 | SRR1341605 | GTEX | — | 0.923 |
| 10 | SRR1398992 | GTEX | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |